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A systematic review was conducted using Samueli Institute’s Rapid Evidence Assessment of the Literature (REAL©)
process to determine the evidence base for melatonin as an agent to optimize sleep or improve sleep quality, and
generalize the results to a military, civilian, or other healthy, active, adult population. Multiple databases were
searched yielding 35 randomized controlled trials (RCTs) meeting the review’s inclusion criteria, which were
assessed for methodological quality as well as for melatonin effectiveness. The majority of included studies were
high quality (83.0%). Overall, according to Grading Recommendations, Assessment Development and Evaluation
(GRADE) methodology, weak recommendations were made for preventing phase shifts from jet lag, for improving
insomnia in both healthy volunteers and individuals with a history of insomnia, and for initiating sleep and/or
improving sleep efficacy. Based on the literature to date, no recommendations for use in shift workers or to
improve hormonal phase shift changes in healthy people can be made at this time. Larger and longer-duration RCTs
utilizing well characterized products are needed to warrant melatonin recommendations in young, healthy adults.
Keywords: Melatonin, Sleep, Systematic review, Rapid evidence assessment of the literature (REAL), Dietary
supplements, Military healthIntroduction
Sleep quality is a problem in the civilian population, where
17.4% of respondents to the 2002 Alternative Health/
Complementary and Alternative Medicine supplement to
the National Health Interview Survey (NHIS) reported in-
somnia or trouble sleeping in the past 12 months [1].
Likewise, sleep quality is a concern within the military.
Data are just beginning to be published regarding sleep
habits and behaviors in the military. A cross-sectional
study of 156 deployed US Air Force Airmen found that
40.0% of respondents suffered from at least one sleep dis-
turbance and 75.0% reported diminished sleep quality
while deployed, as compared to sleep quality at home [2].
A 2010 paper on the Millennium Cohort - 41,225 active
duty and retired Service Members - demonstrated that* Correspondence: patricia.deuster@usuhs.edu
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unless otherwise stated.deployment significantly compromised sleep quality and
quantity [3]. Finally, in 2013, Lentino et al. [4] noted that
over 25% of 14,148 Army Active, Reserve, and National
Guard members reported to be “poor” sleepers, with only
32.9% self-reporting as “good” sleepers. Clearly, obtaining
adequate and good quality sleep are continual challenges
for active duty Service Members during training and dur-
ing periods of deployment. Although sleep promoting
medications, such as zolpidem, are available and widely
used by military personnel for both sleep problems and fa-
tigue management [5], they have been associated with
various adverse effects, including cognitive impairments
[6,7] and in some cases “somnambulism-like state with
sleep-related complex behavior.” Thus, more natural
solutions to the military “sleep problem” must be sought.
The dietary supplement, melatonin, may be one natural
solution.
Exogenous melatonin, as both prescription and over
the counter pills/tablets, has become one of the most
frequently requested non-prescription sleep aids due tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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rhythms, including promotion/regulation of sleep [8].
Melatonin is marketed to help promote total sleep time,
aid with fatigue from jet lag, or balance circadian
rhythms from jet lag and rotating shift work. Evidence
suggests melatonin may reduce the time it takes for
people with delayed sleep phase syndrome (i.e., sleep is
delayed by two or more hours beyond the conventional
bedtime, causing difficulty in waking at a desired time)
to fall asleep [9]; melatonin may also help re-set the
body’s sleep-wake cycle [10]. Importantly, melatonin has
been shown to serve as a mediator between the thermo-
regulatory and arousal system in humans, such that ex-
ogenous administration of melatonin during the day can
result in sleepiness in association with reduced core
temperature [11,12].
Of interest, approximately 5.2% of the NHIS survey re-
spondents reported using melatonin and 27.5% of those
users reported insomnia as a reason for taking the supple-
ment [1]. Some studies have shown that supplemental
melatonin can increase sleep propensity, although it may
not be as effective as prescription sleep medications [13].
If melatonin were found to be effective for promoting
healthy sleep, it could be a useful and suitable sleep aid for
military as well as other populations, where sleep prob-
lems are a serious concern.
Although a small number of systematic reviews have
investigated melatonin’s effects on specific clinical condi-
tions, to date no systematic reviews have explored mela-
tonin across all aspects of sleep behavior in an otherwise
healthy population. Thus, the purpose of this systematic
review was to: 1) determine the evidence base for mela-
tonin to optimize sleep (e.g., improve sleep quality, dur-
ation, ability to fall asleep); 2) evaluate the safety of
melatonin use; 3) assess outcomes and dosing structure
most applicable for this research; and 4) generalize re-
sults to those (e.g., at risk military populations) who suf-
fer from issues related to sleep disturbances and sleep
hygiene [14-21]. This review also discusses strengths,
weaknesses, and gaps emerging from the review, as well
as recommendations for moving this research field for-
ward, in particular with regard to the usefulness of mela-
tonin for military populations in need of sleep regulation
as well as other populations with similar sleep issues.
Methods
A systematic review was conducted using the Rapid Evi-
dence Assessment of the Literature (REAL©) process, a
methodology developed by Samueli Institute to provide a
“snapshot” of the peer-reviewed literature in a streamlined
and efficient fashion. The REAL process differs from trad-
itional systematic reviews in that it does not “exhaustively”
search the literature by including grey and non-English
language literature, but instead includes only randomizedcontrolled trial (RCT) and systematic review study designs
accessible in current English electronic databases. Following
REAL methodology, a research question was developed
with subject matter experts (SMEs) by using the evidence-
based Population, Intervention, Comparison, Outcome
(PICO) framework [22] to assess the effectiveness of
melatonin on mitigating poor sleep and/or promoting
healthy sleep as published and reported in RCTs.
Data sources and search strategy
PubMed/MEDLINE, CINAHL, Embase, PsycInfo, and
Agricola databases were searched from database inception
until October 2012 for RCTs investigating the relationship
between melatonin and healthy sleep behaviors. Authors
explored MeSH terminology within MEDLINE and con-
sulted with three subject matter experts (PAD, CVL, RBC)
to not only strategize the most powerful search, but to also
ensure the correct key terms were being targeted for the re-
search question proposed. The following search strategy
was conducted in PubMed, and MeSH was applied where
applicable: “(melatonin) and (sleep or fatigue or sleep disor-
ders, circadian rhythm or insomnia).” Following traditional
REAL methodology, which includes the assessment of
RCTs involving humans and published in the English lan-
guage, all searches were conducted using these parameters.
Where this was not a limit option in certain databases, cita-
tions were screened for these criteria.
Study selection
Articles were included if they met the following criteria: 1)
RCT presented in the English language and involving
adult human subjects; 2) healthy non-military or military
populations, or populations diagnosed with insomnia, as
reported by the study’s authors; 3) use of melatonin as the
sole intervention; and 4) at least one sleep outcome of
interest (e.g., sleep quality, sleep latency, sleep duration).
Articles were excluded if they met at least one of the fol-
lowing criteria: 1) any study design other than a RCT; 2)
population with pre-existing conditions or diseases other
than insomnia; 3) focus of article was on an intervention
other than melatonin; 4) intervention was a combination
of melatonin and other supplements or drugs; or 5) article
did not have at least one sleep outcome of interest.
Data extraction
In order to streamline the systematic review process in a
secure manner and ensure reliability and consistency
across reviewer ratings, the authors conducted the review
within the web-based systematic review management pro-
gram Mobius Analytics SRS (Copyright 2003–2009
Mobius Analytics Inc, Ottawa, Ontario). This program re-
duces errors and post-review data collation, and increases
reviewer efficiency by automating article progression and
management.
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methodological quality using the Scottish Intercollegiate
Guidelines Network (SIGN 50) checklist, a reliable and valid
assessment tool widely used in the literature [23] (Table 1).
Three trained reviewers (MLO, MLS, CCB) reviewed articles
in pairs until a sufficient kappa (>90%) was achieved, at
which point they independently reviewed the remaining arti-
cles. All work was cross-checked by the review manager
(CCC), and disagreements were resolved either through dis-
cussion and consensus, or by one of the SMEs.
The following descriptive data were extracted for each
of the included studies: population description, sample
size, melatonin and control interventions and dosages,
all sleep related outcomes and statistics, funding source,Table 1 Sign 50 checklist for RCT study design [23]
Section 1: Internal validity1
Item Criteria
1.1
The study addresses an appropriate and clearly focused
question.
1.2
The assignment of subjects to treatment groups is
randomized.
1.3 An adequate concealment method is used.
1.4
Subjects and investigators are kept blind about treatment
allocation.
1.5
The treatment and control groups are similar at the start
of the trial.
1.6
The only difference between groups is the treatment
under investigation.
1.7
All relevant outcomes are measured in a standard, valid
and reliable way.
1.8
What percentage of subjects in each treatment arm
dropped out before the study was completed?
1.9
All subjects are analyzed in the groups to which they were
randomly allocated (intention-treat analysis).
1.10
Where the study is carried out at more than one site,
results are comparable for all sites.
Section 2. Overall Assessment
Quality
Score Criteria
++
All or most of the criteria have been fulfilled adequately
or well. Where they have not been fulfilled the conclusions
of the study are thought very unlikely to alter. An article
receives this score if there are 0 criteria scored as poorly
addressed.
+
Some of the criteria have been fulfilled adequately or well.
Those criteria that have not been fulfilled or not
adequately described are thought unlikely to alter the
conclusions. An article receives this score if 1-3 criteria are
scored as poorly addressed.
-
Few or no criteria fulfilled adequately or well (3 or more
poorly addressed criteria). The conclusions of the study
are thought likely or very likely to alter. An article receives
this score if more than 3 criteria are scored as poorly
addressed.
1Each item is evaluated as well covered, adequately addressed or poorly
addressed. Item 1.10 can also be marked as not applicable.author’s main conclusions and whether power calcula-
tions, adverse events, and cost analyses were reported.
Additional study design elements deemed important for
quality control of dietary supplement studies were also
extracted from each study, including characterization of
the intervention product, baseline exposure or back-
ground diet (e.g. use of dietary supplements) of the study
participants, and whether or not dietary intake was con-
trolled during the study. Additionally, data regarding
melatonin supplement formulation and whether or not
it was analyzed for purity and absorption after ingestion
were gathered.
Data synthesis and analysis
Once the quality assessment of individual RCT study re-
ports was completed, the SMEs performed a quality as-
sessment of the overall literature pool for each identified
population by using a modification of the Grading of
Recommendation Assessment, Development and Evalu-
ation (GRADE) [24], an internationally accepted ap-
proach to grading the quality of evidence and strength
of recommendations across studies. SMEs were trained
in this methodology and utilized a grading rulebook de-
veloped, tested and agreed upon by the entire team.
SMEs examined the outcomes of the individual RCTs
for each category of intended use (i.e., shift workers, jet
lag, insomnia, healthy volunteers) in order to: 1) exam-
ine the confidence in the estimate of the effect; 2) deter-
mine the magnitude of the effect size overall; 3) assign a
safety grade to the literature; and 4) develop recommen-
dations for the melatonin literature based on the REAL
results for the overall literature pool of studies for each
category. SMEs performed the GRADE analysis inde-
pendently before discussing their answers together and
coming to consensus with the full team. Due to the het-
erogeneity of included individual studies, outcome data
were not pooled for statistical analysis.
Results
The results of the initial database search yielded 557 ref-
erences, 39 of which met the inclusion criteria and were
subsequently included in the review. Articles were ex-
cluded mostly because the intervention was not mela-
tonin or because they did not report on sleep related
outcomes. Of these 39 included articles, four [25-28] re-
ported on different outcomes of the same study and
were, therefore, combined with their appropriate coun-
terpart. Ultimately, 35 RCTs, with a total of 2,356 sub-
jects, were included in this review (see Figure 1 for the
flow chart of included studies).
Table 2 describes the characteristics of the individual
studies (grouped by shift workers, jet lag, insomnia, and
healthy volunteers) and overall SIGN 50 score. Table 3 de-
scribes the GRADE analysis results of the overall literature
Figure 1 Flow chart of included studies.
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ered important for dietary interventional studies. Table 5
presents the number and types of subjective and/or ob-
jective assessment tools utilized in this review.
Overall quality assessment of individual included studies
The overall methodological quality of the RCTs was evalu-
ated as being of the highest (++) quality, high (+) quality
or poor (−) quality, according to the SIGN 50 criteria indi-
cated in Table 1 (see Table 2 for quality scores). The ma-
jority (80%) of the 35 included RCTs were high (+) quality,
with one study (3%) being of the highest (++) quality [34].
Conversely, 17.0% of studies were scored as poor quality.
An appropriate and clearly focused research question was
adequately addressed in 80.0% of the trials; the remaining
(20.0%) addressed this area well. Over half (51.0%) of the
studies had dropout rates less than 10.0% and were, there-
fore, considered well-covered for this criterion, whereas
31.0% of studies either did not mention dropout rates or
reported rates greater than 20.0%. Regarding intention-to-
treat analysis, 54.0% of the included studies were classified
as poorly addressed because such analyses were not men-
tioned or described; 3.0% of the studies adequately ad-
dressed intention-to-treat analysis; and 43.0% addressed it
well. Although the majority (86.0%) of studies poorly de-
scribed their methods of allocation concealment, all
(100%) studies adequately addressed blinding methodsregarding treatment allocation. Methods of randomization
were described poorly by 48.0% of the studies; 46.0% ad-
equately described this process and only 6.0% did it well.
Nearly all (97.0%) and the majority (55.0%) of the trials ad-
equately addressed differences between treatment groups
and baseline similarities, respectively. Results indicated
that 51.0% of articles adequately covered outcome validity
and reliability, whereas 37.0% covered this criterion well.
Three studies [28,29,62] were multi-site, and one [28]
poorly addressed the comparability of results among sites;
the remaining two were well covered [29] or adequately
addressed [62] in this area.
Adverse events
Of the total 35 studies included in our analysis, 15
[29,30,33,34,36,38,39,41-47,52] included information on
adverse events. No serious adverse events were re-
ported. One [36] study reported that adverse events oc-
curred, but did not describe them, and two [34,45]
reported no adverse events occurred at all. The most
common adverse events were headache [29,33,44,46,47]
and somnolence [33,41,44,48]. Palpitations [42,43] and
abdominal pain [33,43] were each reported in two
studies. The remaining adverse events were reported
infrequently, and each occurred in only one of the mul-
tiple studies: nasopharyngitis [46], arthralgia [46], tachy-
cardia [39], dizziness [33], nausea [33], vomiting [33],
Table 2 Characteristics and quality score of included studies
Citation Population description Sample entered/completed Melatonin supplement vs. control Outcomes Author's main conclusions Quality
f
Shift Workers (n = 8)
Jorgensen
et al. [29]
20 emergency medicine resident and
attending physicians (age/gender = ND)
at the University of Marylandad
overall (20/20) 10 mg melatonin pill vs. placebo taken
the morning after each night shift
(starting day 2)e
Sleep diary,
SSS, sleep VAS
Melatonin did not significantly improve
night alertness or day sleep in shift
workers, although there was a trend
toward improved night alertness.
+
James et al.
[30]
24 adult emergency medical technicians
or paramedics (age/gender = ND)
working night shiftsac
overall (24/22) 6 mg melatonin pill vs. placebo capsule
taken 30 min before each day sleep
Sleep diaries,
sleep VAS
Melatonin supplements did not improve
sleep quality or duration in emergency
medical services personnel working
rotating night shifts.
+
Sadeghniiat-
Haghighi
et al. [31]
118 healthy non-smoking non-pregnant
shift-worker female nurses (age = ND)
with insomniac
overall (118/86) 5 mg melatonin tablet vs. placebo taken
on the first night after shift work, 30 min
before habitual nighttime sleepe
Questionnaire Melatonin significantly decreased sleep
onset latency (p = NR) and increased
sleep quality as compared with placebo
(p < 0.05).
-
Bjorvatn
et al. [32]
38 oil rig workers, age/gender NDc overall (38/17) 3 mg melatonin capsule vs. placebo
taken 1 h before bedtime vs. bright light
(10,000 lux) applied for 30 min/day,
ranging from midnight (0000) to (0500)
during the night shift and from midday
(1200) to (1430) during the day shifte
KSS, ATS, sleep
diary, 5-min
reaction test,
actigraph
Melatonin reduced sleepiness at work
during the dayshift week (p = 0.016) and
subjectively increased sleep by 15-20
min per day (p = 0.05) compared to
placebo. Objectives measures indicated
that reaction times did not differ
between conditions whereas bright light
improved sleep to a minor degree
(p = 0.04).
-
Cavallo et al.
[33]
45 second year pediatric residents
working two night float periods (16 M/
29 F) with a mean age of 28.6 ± 9ac
overall (45/28) 3 mg melatonin fast release capsule vs.
placebo taken every morning after night
shift worke
Sleep diary,
VAS, POMS
Melatonin treatment did not improve
sleep duration, vigor, or fatigue in shift
workers.
+
Wright et al.
[34]
15 faculty emergency physicians (12 M/3
F) with a mean age of 38.6 ± NDac
overall (15/15) 2 x 2.5 mg melatonin tablets vs. placebo
given 30 min before bedtime
KSS, tiredness
VAS, sleep VAS,
drug
tolerability
VAS,
questionnaire
Melatonin showed no benefit in a group
of emergency physicians after night-shift
work.
++
Sharkey et al.
[35]
21 healthy adults (12 M/9 F) with a
mean age of 27.0 ± 5.0c
overall (21/21) 1.8 mg melatonin sustained-release
tablet vs. placebo taken 30 min before 2
daytime sleep episodese
PSG, saliva
samples, MSLT,
SSS, sleep VAS,
sleep diary,
actigraph
Melatonin prevented the decrease in
sleep time that occurs from sleeping at
the ‘wrong' circadian phase (p < 0.05).
Subjects taking melatonin were sleepier
at bedtime (p = 0.003) on sleep day 1
compared to placebo.
+
Jockovich
et al. [36]
19 volunteer emergency medicine
residents (15 M/4 F) with a mean age of
28.2 ± NDac
overall (19/19) 1 mg melatonin caplet vs. placebo taken
30-60 min prior to anticipated daytime
sleep session following a night shifte
SSS, wrist
actigraph
Melatonin did not improve daytime
sleep for emergency physicians working
night shifts.
+
Jet Lag (n = 8)
Arendt et al.
[37]
17 healthy volunteers (7 M/10 F) with
mean age of 48.5 ± 2.2c
overall (17/17), melatonin
(8/8), placebo (9/9)
5 mg melatonin capsule vs. placebo
taken at 1800 h on the day of their
transcontinental flight departure for the
VAS mood,
VAS sleep, VAS
Melatonin is effective in subjectively
alleviating jet lag (p < 0.01) following
eastward travel over eight time zones.
+
C
ostello
et
al.N
utrition
Journal2014,13:106
Page
5
of
17
http://w
w
w
.nutritionj.com
/content/13/1/106
Table 2 Characteristics and quality score of included studies (Continued)
two preceding days, and between 2200-
2400 h on the first four days after their
return flight
jet lag, urine
samples
Spitzer et al.
[38]
339 Norwegian physicians (203 M/136 F)
with a mean age of 44 ± 7ac
overall (339/257) 5 mg or 0.5 mg melatonin capsules vs.
placebo taken daily at bedtime on travel
day and post-travel days 1-5
Columbia jet
lag scale
Melatonin did not effectively treat
jet lag. -
Claustrat
et al. [39]
37 participants accustomed to
intercontinental flights who usually
experience subsequent discomfort after
an eastward journey (18 M/12 F) with a
mean age of 36.3 ± 8.9 in the melatonin
group and 35.7 ± 6.4 in the placebo
groupd
overall (37/27) 8 mg melatonin capsule vs. placebo
taken on day 1 (2200 h) and days 2-4 at
bedtime
Global
treatment
efficiency VAS,
sleepiness and
mood VAS,
sleep VAS
Melatonin demonstrated an overall
efficiency in alleviating jet lag (p < 0.058)
in subjects who experienced significant
discomfort after an eastward flight,
compared to placebo.
+
Beaumont
et al. [40]
27 participants from a US Air Force
Reserve Unit (18 M/9 F) with a mean
age of 35.3 ± 8.1c
overall (27/27), slow-release
caffeine (9/9), melatonin
(9/9), placebo (9/9)
5 mg melatonin pill vs. 300 mg slow-
release caffeine vs. placebo administered
preflight (1700 h) and daily from day 1
(arrival day; 1600 h) - day 5 (2300 h)
PSG, sleep
diary, MSLT,
piezoelectric
accelerometer,
sleep VAS
Melatonin decreased sleepiness
subjectively (p < 0.05), but not
objectively, and improved recovery sleep
(p < 0.05), indicating some value for
alleviating symptoms related to jet lag
combined with sleep deprivation.
+
Petrie et al.
[41]
20 volunteers with experience of
transcontinental flights through at least
5 time zones (12 M/8 F) with an age
range from 28-68c
overall (20/20) 5 mg melatonin capsule vs. placebo
taken once a day on pre-flight days 1-3
(between 1000 h and 1200 h), during
flight, and once a day for post-flight
days 1-3 (between 2200-2400 h)e
VAS, POMS,
hours of sleep,
retrospective
jet lag ratings
Melatonin use resulted in significantly
less overall jet lag compared to placebo
(p < 0.01). Subjects taking melatonin
reported that they were less tired during
the day and required less time to
establish a normal sleeping pattern
(p < 0.05) and reach their normal level
of energy (p < 0.05).
+
Suhner et al.
[42]
160 recruited volunteer travelers (age/
gender = ND) planning a trip from
Switzerland to the American continent
through 6 to 9 time zones and staying
there at least 1 wk. before returningc
melatonin (ND/35)
zolpidem (ND/34)
melatonin + zolpidem
(ND/29)
5 mg melatonin capsule vs. placebo vs.
10 mg Zolpidem vs. a combination of 5
mg melatonin + 10 mg Zolpidem taken
on the return flight (eastbound) between
1700-2100 h and during 4 consecutive
days post-flight at bedtime
Sleep diary,
POMS, jet lag
VAS, symptom
assessments,
actigraph
Melatonin reduced jet lag severity to
some extent (p < 0.05). However,
Zolpidem 10 mg was the most effective
treatment in that it significantly
improved subjective sleep quality on
night flights (p < 0.05), reduced over-all
jet lag feelings and alleviated sleep
disturbances and confusion associated
with jet lag (p < 0.05).
+
Suhner et al.
[43]
320 volunteers who had flights over 6-8
time zones (172 M/148 F) with a mean
age of 36 ± NDc
overall (320/234) melatonin
(ND/174) placebo (ND/60)
5 mg fast-release (FR), 0.5 mg FR, or 2
mg controlled-release melatonin vs.
placebo taken once daily at bedtime
during 4 days after an eastward flight
POMS, sleep
diary,
symptom
questionnaire,
KSS
Melatonin significantly improved self-
rated sleep quality (p < 0.05), shortened
sleep latency (p < 0.05), and reduced
fatigue (p < 0.05) in subjects with jet
lag. Melatonin 5 mg formulation was the
most effective dosage to reduce fatigue
and sleep disorders associated with jet
lag after eastbound flights.
+
Petrie et al.
[44]
52 participants from an Air New Zealand
cabin crew (26 M/25 F) with a mean age
of 34.9 ± 7.7 c
overall (52/44) 5 mg melatonin capsule vs. placebo
taken daily between 0700-0800, 2-3 days
prior to return flight, and between 2200-
0000 h until 5 days after return homee
VAS, SSS,
retrospective
jet lag VAS,
POMS
Melatonin reduced the subjective effects of
jet lag, reduced feelings of jet lag (p < 0.05)
and led to a more rapid recovery of sleep
and energy levels (p < 0.05).
+
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Insomnia (n = 4)
Almeida
Montes et al.
[45]
10 insomnia patients (6 M/4 F) with a
mean age of 50 yrs. ± 12.7c
overall (10/10) 0.3 mg or 1 mg sustained-release mela-
tonin capsules vs. placebo taken 60 min
before bedtime, (bedtime between
2200-2300 h) for 7-day treatment periode
PSG, VAS, sleep
diary
elatonin did not affect sleep quality in
atients with primary insomnia.
+
Wade et al.
[28]Wade
et al. [46]
791 participants (age/gender = ND) with
primary insomnia according to the DSM-
IV criteriaac
treatment period: overall
(791/748), PRM (395/374),
placebo (396/374); extension
period: overall (711/555),
PRM (534/421), placebo
(177/134)
2 mg prolonged-release Circadin pill vs.
placebo taken daily 1-2 h before bedtime
(bedtime between 2100-2200 h)
National sleep
foundation
diary, PSQI
elatonin (Circadin) significantly increased
leep time (p = 0.035) for individuals
8-80 years compared to placebo.
+
Garfinkel
et al. [47]
34 patients (9 M/25 F) with a mean age
of 68 ± 13 who were willing to
discontinue current benzodiazepine
therapy at some point during the studyc
overall (34/30), CRM (18/15),
placebo (16/15)
2 mg Circadin pill vs. placebo taken 2 h
before bedtime (bedtime between 2100-
2300 h)
Subjective
sleep quality
questionnaire
elatonin significantly improved sleep
uality (p = 0.04) compared to placebo,
dicating that controlled-release melatonin
ay effectively facilitate discontinuation of
enzodiazepine therapy while maintaining
ood sleep quality.
+
James et al.
[48]
10 participants (4 M/6 F) with a diagnosis
of Disorder in Initiating or Maintaining
Sleep with a mean age of 33.4 ± NDd
overall (10/10) 1 mg or 5 mg melatonin pill vs. placebo
taken 15 min before bedtime (2300 h)e
DSQ, VAS, SSS
EEG
elatonin 1 mg significantly increased
EM latency (p < 0.05), and produced a
ignificant delay in REM latency after
edtime administration (p < 0.05).
elatonin 5 mg resulted in less sleep
= 0.02) and an improvement in
verall subjective sleep quality (p = 0.03)
ompared to 1 mg and placebo.
+
Healthy Volunteers (n = 17)
Initiation of Sleep/Sleep Efficacy (n = 7)
Paul et al.
[49] Paul
et al. [25]
23 military and civilian volunteers (9 M/
14 F) with a mean age of 29.9 ± 10.3c
overall (23/ND) 6 mg time-released Circadin pill vs. placebo
vs. 10 mg Zaleplon pill vs. 7.5 mg Zopiclone
pill vs. 15 mg Temazepam pill taken at
0945 h on one of 5 experimental dayse
PSG, 7 point
Likert
drowsiness
scale
elatonin use significantly increased
leep (p < 0.05), decreased sleep latency
< 0.05), and increased drowsiness
< 0.0001) immediately after psychomotor
sting compared to before testing for all
edications. Melatonin increased sleep
nd reduced sleep latency (p < 0.05) after
sychomotor test sessions from 1 3/4h to 4
/4h post-ingestion. Melatonin significantly
rolonged subjective sleepiness (p < 0.001);
owever, the largest effects on total sleep,
leep latency and drowsiness were
ttributable to Zopiclone.
+
James et al.
[50]
10 participants (7 M/3 F) with a mean
age of 29.9 ± NDd
overall (10/10) 1 mg or 5 mg melatonin pill vs. placebo
taken at 2245 h for one of three weeks
PSG elatonin 5 mg significantly prolonged
EM latency (p < 0.001), suggesting that
larger dosage of melatonin may
fluence sleep and circadian rhythms.
+
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Table 2 Characteristics and quality score of included studies (Continued)
Nave et al.
[51]
6 healthy males with a mean age of
24.5 ± 0.9c
overall (6/6) 3 mg melatonin pill vs. placebo vs.
10 mg Flumazenil + placebo vs. 10 mg
Flumazenil + 3 mg melatonin taken at
1200 h for one of four 7 h (1200-1900 h)
testing periods
PSG, actigraph elatonin significantly decreased latency
the first appearance of sleep (p < 0.05)
nd increased total sleep time (p < 0.05). +
Middleton
et al. [52]
10 normal healthy male soldiers with a
mean age of 23.90 ± 0.75c
overall (10/8) 5 mg melatonin capsule vs. placebo
taken at 2000 h, 1200 or 0400 h for
15 dayse
Sleep diaries,
urine samples
elatonin produced significant
ifferences for sleep onset, sleep offset
nd activity acrophase (p < 0.001),
dicating a sleep phase shift.
+
Aeschbach
et al. [53]
8 volunteers (4 M/4 F) with a mean age
of 27.8 ± 3.6c
overall (8/8) 2.1 mg melatonin patch vs. placebo
patch given one hour before 8 h daytime
sleep opportunity (between 0900-1700 h)
on day 2 of a 36 h inpatient visite
PSG, KSS,
blood sample
ransdermal melatonin delivered during
e daytime elevated plasma melatonin
< 0.0001) and reduced waking (p < 0.05)
fter sleep onset by promoting sleep
< 0.05) in the latter part of an 8 h sleep
pportunity.
+
Attenburrow
et al. [54]
15 healthy middle aged volunteers (4 M/
11 F) with a mean age of 53.9 ± NDc
overall (15/12) 0.3 mg or 1 mg melatonin pill vs.
placebo given 2h before bedtime
(bedtime between 2200-2300 h) for 3
separate nightse
PSG, Leeds
sleep
evaluation
questionnaire
elatonin improved actual sleep time
< 0.02), sleep efficiency (p < 0.02),
on-REM sleep (p < 0.03) and REM sleep
tency (p < 0.05) in healthy, middle-aged
olunteers sleeping in their home
nvironment.
-
Van Den
Heuvel et al.
[55]
10 healthy male volunteers with a mean
age of 22 ± 1.1c
overall (10/10) 100 mg atenolol pill + 1 mg melatonin
pill vs. placebo pill vs. 100 mg atenolol
pill + placebo pill taken at 1900 h, 2200,
0200, or 0400 h during 3 nonconsecutive
nights in the sleep laboratorye
MSLT, linear
sleepiness
rating
elatonin did not affect sleep onset
tencies and subjective sleepiness.
+
Daytime Sleepiness (Occurrence Of)/Somnolence (n = 5)
Rose et al.
[56]
68 participants (age/gender = ND)
recruited from Santa Clara Universityac
overall (68/53) 2 x 3 mg melatonin capsules vs. placebo
taken 30 min before bedtime for 8 nightse
DSSEQ elatonin facilitated an increase in
rogginess/ tiredness prior to sleep
nset (p = 0.01). Additionally, the
xpectancy of receiving melatonin
sulted in significantly higher mean
tings of grogginess/tiredness
= 0.02).
+
Rogers et al.
[57]
16 young healthy subjects (6 M/10 F)
with a mean age of 21.4 ± 6c
overall (16/16) 5 mg melatonin capsule vs. placebo vs.
10 mg Temazepam capsule taken at
1200 h during 1 of 3 experimental
sessions, each lasting from 2200 until
1900 h the following daye
VAS elatonin and Temazepam both
roduced a significant increase in
elf-reported sleepiness levels (p = 0.02)
lative to placebo. However, melatonin
se led to a steady increase in self-reported
leepiness levels (p = 0.006) compared to
oth Temazepam and placebo.
+
Krauchi et al.
[58]
8 healthy male students with a mean
age of 25 ± 4c
overall (8/8) 5 mg melatonin capsule vs. placebo
taken once at 1300 he
VAS, KSS,
waking EEG
elatonin administration at 1340, 1420,
510, 1550, and 1620h increased
leepiness (p < 0.05).
+
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Table 2 Characteristics and quality score of included studies (Continued)
James et al.
[50]
10 participants (7 M/3 F) with a
mean age of 29.9 ± NDd
overall (10/10) 1 mg or 5 mg melatonin pill vs. placebo
taken at 2245 h daily for one week
DSQ, VAS, SSS Melatonin did not produce differences in
daily sleep or sleepiness between
groups.
+
Nave et al.
[51]
6 healthy males with a mean age
of 24.5 ± 0.9c
overall (6/6) 3 mg melatonin pill vs. placebo vs.
10 mg Flumazenil + placebo vs. 10 mg
Flumazenil + 3 mg melatonin taken at
1200 h for one of four 7 h (1200-1900 h)
testing periods
VAS Melatonin 3 mg significantly increased
sleepiness (p < 0.02) when administered
at 1200 h in the placebo + melatonin
and flumazenil + melatonin conditions.
+
Phase Shift/Hormone Changes (n = 5)
Bonafide
et al. [59]
12 healthy volunteers
(age/gender = ND)ac
overall (12/10) 3 mg melatonin pill + Saline (80 ml/h) IV
vs. 3 mg melatonin pill + Remifentanil
(0.02-0.04 ug kg) IV vs. placebo + Saline
(80 ml/h) IV vs. Remifentanil (0.02-0.04
ug kg) IV + placebo, administered at
2230 he
PSG, sleep
diary
Melatonin did not alter normal nocturnal
sleep or prevent remifentanil-induced
sleep disturbance.
+
Luboshitzky
et al. [60]
6 healthy males with a mean
age of 23.9 ± 2.4c
overall (6/5) 6 mg melatonin pill vs. placebo once a
day at 1700 h for 1 month
PSG Neither melatonin nor the control
influenced the majority of
polysomnographic sleep parameters,
however, melatonin did significantly
increase REM latency (p < 0.04) and
percent REM (p < 0.05) compared to
baseline.
-
Gorfine et al.
[61]
12 participants (2 M/10 F) with
a mean age of 25 ± 4.8c
overall (12/ND) 2 mg melatonin drink (100 ml of 1%
ethanol in water) vs. placebo drink
administered every 2-3 h, starting at
1600–1700 he
Bond-Lader
questionnaire
Melatonin caused significant increases
from predosing scores in self-reported
parameters of fatigue (p < 0.001), sleepi-
ness (p < 0.001), dreaminess (p < 0.01) and
boredom (p = 0.02) and significant
decreases in lucidness (p = 0.03).
-
Vandewalle
et al. [62]
Rajaratnam
et al. [26]
Rajaratnam
et al. [27]
8 male subjects with a mean
age of 24.4 ± 4.4c
overall (8/8) 1.5 mg surge-sustained-release melatonin
pill vs. placebo taken at 1600 h during
daily scheduled 16 h sleep opportunities
for 8 consecutive dayse
HR/HRV, blood
samples,
actigraph, KSS,
PSG.
Melatonin successfully phase-shifted
circadian rhythms (p < 0.045) without
indication of deleterious effects on
daytime sleepiness/mood on the day fol-
lowing administration.
+
Paul et al.
[63]
11 normal healthy male volunteers
with a mean age of 38.2 ± 9.7ac
overall (11/11) 3 mg sustained release melatonin
capsule vs. light treatment + 3 mg
melatonin capsule vs. placebo capsule
vs. light treatment. Capsules were
administered at 1600h on day 2, light
treatment from 0600-0800h on day 3e
Melatonin
assays, saliva
samples,
actigraph
Melatonin significantly increased phase
advances compared to placebo
condition (p < 0.0002).
+
ATS = Accumulated Time with Sleepiness scale, CRM = controlled-release melatonin, DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, DSQ = Daily Sleep Questionnaire, DSSEQ = Daily
Subjective Sleep Experiencing Questionnaire, EEG = Electroencephalogram, F = female, h = hour, HR = heart rate, HRV = heart rate variability, KSS = Karolinska Sleepiness Scale, M = male, mg = milligram, MSLT = Mul-
tiple sleep latency test, n = number, ND = not described, NR = not reported, POMS = Profile of Mood States, PRM = Prolonged-release circadin, PSG = Polysomnographic recording, PSQI= Pittsburgh Sleep Quality
Index, REM = Rapid eye movement, SSS = Stanford Sleepiness Scale, VAS = Visual Analog Scale, wk = week apower achieved, bpower not achieved, cinformed consent obtained, dinformed consent not obtained,
ecrossover design.
fSee Table 1: Quality refers to the overall SIGN 50 score, categorized as ++ (well covered; where criteria has not be filled, conclusions of the study are thought very unlikely to alter); + (adequately addressed; criteria
that have not been adequately described are thought unlikely to alter conclusions) or – (poorly addressed; conclusions of study are thought likely or very likely to alter).
Note. Four [25-28] RCTs reported on different outcomes of the same study and were therefore combined; the most recent study was cited in the paper.
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Table 3 Grading of Recommendations Assessment, Development and Evaluation (GRADE) analysis: quality of the
overall literature pool assessing melatonin for the promotion of healthy sleep patterns
Category Number of participants
completed (Number of studies)
Confidence in estimate
of Effect GRADE1
Magnitude of estimate
of Effect GRADE2
Safety
GRADE3
Strength of the
Recommendation4
Shift Workers 300 (8) C ND +1 None
Jet Lag 972 (8) B ND +1 Weak, in favor
Insomnia 845 (4) B ND +1 Weak, in favor
Healthy Volunteers
Initiation of Sleep/Sleep
Efficacy
82 (7)* B ND 0 Weak, in favor
Occurrence of Daytime
Sleepiness/Somnolence
108 (5)* B ND 0 Weak, in favor
Phase Shift Changes 49 (5) C ND 0 None
*2 Studies [50,51] mentioned in both groups.
There are four major domains that comprise the core of the modified GRADE methodology:
1Categorized as A (High; further research is very unlikely to change confidence in the estimate of effect); B (Moderate; further research is likely to have an
important impact on confidence in the estimate of effect and may change the estimate); C (Low; further research is very likely to have an important impact on
confidence in the estimate of effect and is likely to change the estimate)or; D (Very Low; any estimate of effect is very uncertain).
2Categorized as none (<0.2), small (0.2 – 0.5), moderate (0.5 – 0.8), large (>0.8) or not described (ND; authors did not describe or report effect size for this review’s
outcomes of interest due to the lack of author reporting).
3Dependent on the frequency and severity of adverse events and interactions; as +2 (appears safe with infrequent adverse events and interactions); +1 (appears
relatively safe but with frequent but not serious adverse events and interactions); 0 (safety not well understood or conflicting); −1 (appears to have safety
concerns that include infrequent but serious adverse events and/or interactions) or; −2 (has serious safety concerns that include frequent and serious adverse
events and/or interactions).
4Strength of the recommendation can be determined using the following categories and criteria: Strong recommendation in favor of or against (very certain that
benefits do, or do not, outweigh risks and burdens); No recommendation (no recommendations can be made) or; Weak recommendation in favor of or against
(benefits and risks and burdens are finely balanced, or appreciable uncertainty exists about the magnitude of benefits and risks).
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http://www.nutritionj.com/content/13/1/106nightmares [33], difficulty swallowing and breathing [38],
hypnotic activity [39], heavy head [39], heartburn [43],
flatulence [43], swelling of arms/legs [43], sweating/hot
flash [43], exanthema [43], sleeping difficulties [44], de-
pression [44], problems with the rectal probe [52], and
sleep walking [42].
Effectiveness of melatonin for promoting healthy sleep
outcomes
Included studies were categorized according to the intended
use of melatonin in 1) shift workers and individuals with jet
lag to rebalance the sleep-wake cycle; 2) persons with in-
somnia to promote sleep; and 3) in healthy volunteers to im-
prove outcomes of sleep efficacy, somnolence, and/or
hormonal phase shift changes (see Table 2 for full descrip-
tion of included studies and Table 3 for GRADE Analysis).
Shift workers
Eight [29-36] RCTs with 300 total participants assessed
the efficacy of melatonin for promoting sleep in shift
workers. The majority of studies were of either high (+)
[29,30,33,35,36] [or highest (++) quality [34], with two
[31,32] poor (−) quality RCTs suffering from inadequate
reporting of dropout rates, concealment methods, and
baseline differences between groups. Results indicated
that both of the poor quality studies favored melatonin
[31,32] however, all of the high and highest quality stud-
ies were inconclusive [29,30,33-36] in that they favored
neither melatonin nor the control. Based on the five[29,30,33,34,36] studies that reported adverse events,
melatonin appears to be relatively safe, with frequent but
not serious adverse events and interactions. Despite its
apparent safety, and the general high quality of this lit-
erature pool, sample sizes were generally small, and re-
sults inconclusive, with no magnitude of an estimate of
effect size reported. Consequently, the SMEs were not
able to give any recommendation for the use of mela-
tonin in shift workers at this time.
Jet Lag
Eight [37-44] RCTs with 972 total participants character-
ized melatonin use for counteracting jet lag. Almost all of
the studies were of high (+) quality [37,39-44], with the
exception of one poor (−) quality study [38], which fa-
vored neither melatonin nor control, despite a large sam-
ple size (n = 339). Of the seven high (+) quality studies,
one [40] favored neither melatonin nor control. The
remaining six [37,39,41-44] RCTs favored melatonin, in-
cluding two [42,43] large studies (n = 320 [44] and n = 160
[41]) and one [39] which noted a limitation that melatonin
increased tiredness the next morning. Melatonin appears
to be relatively safe based on the six [38,39,41-44] studies
that reported adverse events, citing occasional, but not
serious adverse events and interactions. Based on the high
quality and favorable results reported, the SMEs con-
cluded that in a jet lagged population, further research
may have an impact on the confidence in the estimate of
the effect, and as such, provide a weak recommendation
Table 4 Reporting of dietary supplement design elements
Jet lag
(n = 8)
Insomnia
(n = 4)
Healthy volunteers
(n = 15)
Shift workers
(n = 8)
Total N
(%)
Assessment of baseline exposure 0/8 2/4 2/15 0/8 4/35 (11%)
Control for background diet 5/8 1/4 11/15 4/8 21/35 (58%)
Description of Melatonin preparation 1/8 3/4 11/15 5/8 20/35 (57%)
Chemical analysis of Melatonin preparation 2/8 0/4 3/15 1/8 6/35 (17%)
Absorption analysis of the Melatonin preparation 1/8 2/4 9/15 1/8 13/35 (37%)
Total N (%) 9/40 (22%) 8/20 (40%) 16/75 (48%) 11/40 (27%)
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cycle in people with jet lag.Insomnia
Four studies of high (+) quality [45-48] with 845 total par-
ticipants assessed the efficacy of melatonin in promoting
better sleep in persons with insomnia. Two [45,48] of
these studies favored neither melatonin nor control, while
the remaining two [46,47] including one large study
(n = 791) [46] favored melatonin, Similar to the results in
jet lag studies, limitations in sample size compromised the
power to produce an effect in populations with insomnia.
Despite the trend in small sample sizes and lack of effect
size reporting, all four studies were high quality, showing
positive effects and infrequent, non-serious adverse
events; as a result, the SMEs give a weak recommendation
in favor of melatonin when used to promote sleep in
persons with insomnia, with the understanding that the
introduction of more large, high quality studies may have
an important impact on this recommendation, andTable 5 Objective and subjective outcome measures captured
Outcome name Sh
wor
Objective measures
Polysomnographic recording (PSG)*; Actigraph*; Saliva samples**;
Blood samples**; Electroencephalogram (EEG)*; Accelerometers*;
Hours of sleep*; Heart rate/Heart rate variability (HR/HRV)*; Melatonin
assays*; Multiple sleep latency test(MSLT)*; Urine samples**; 5- min
reaction test*
7
Subjective measures
Visual Analog Scale (VAS)*; Sleep diaries; Stanford Sleepiness Scale
(SSS)*; Profile of Mood States (POMS)*; Karolinska Sleepiness Scale
(KSS)*; Daily Sleep Questionnaire (DSQ); Questionnaire; 7 point Likert
Drowsiness Scale; Accumulated Time with Sleepiness Scale (ATS)*;
Accumulated Time with Sleepiness Scale (ATS)*; Bond-Lader
Questionnaire; Columbia Jet Lag Scale*; Daily Subjective Sleep
Experiencing Questionnaire (DSSEQ); Leeds Sleep Evaluation
Questionnaire*; Linear Sleepiness Rating; Pittsburgh Sleep Quality
Index (PSQI)*; Retrospective ratings; Subjective Sleep Quality
Questionnaire; Symptom assessments; Symptom questionnaire
2
*Validated Measures.
**Objective measures captured to determine melatonin bioavailability but not relevpotentially change the confidence in the estimate of the ef-
fect size.Healthy volunteers
Fifteen [28,49-61,63] RCTs with a total of 223 participants
described melatonin use for promoting sleep in healthy
volunteers. Of the 15 total studies, 12 [49-53,55-59,62,63]
were high (+) quality and the remaining three [54,60,61]
were poor (−) quality. Two [54,61]of the poor quality
studies favored melatonin, whereas the third [60] favored
neither melatonin nor control. Of the high quality studies,
eight [49,51-53,56-58,62] indicated favorable results for
melatonin, although six [51-53,57,58,62] had small sample
sizes (n = 6 to 23; total subjects for six studies = 71). The
remaining four [50,55,59,63] high quality studies showed
no beneficial effects for either melatonin or control
groups.
Healthy volunteers were furthered subdivided into three
groups based on the sleep outcome under evaluation: initi-
ation of sleep/sleep efficacy [36,49-51,53-55], occurrence ofin the review
ift
kers
Jet
lag
Insomnia Initiation of
Sleep/Sleep
efficacy
Daytime sleepiness
(occurrence of)/
Somnolence
Phase shift/
hormone
changes
6 2 9 1 9
1 24 8 5 6 3
ant outcomes of interest to this review.
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tion of phase shift/hormone changes [59-63]. Two studies
[50,51] included both initiation of sleep/sleep efficacy and
occurrence of daytime sleepiness/somnolence outcomes,
and were consequently included in both categories. Results
for each group are described below.
Initiation of sleep/sleep efficacy
All except one [54] of the seven studies investigating the
effect of melatonin on initiation of sleep or sleep efficacy
were scored high quality, and five [49,51-54] of them
showed results in favor of melatonin. Because only one
[52] study in this group reported on adverse events, cit-
ing a problem with the rectal probe, safety is not well
understood. Similarly, effect sizes were not reported.
Despite the lack of safety and effect size reporting and
small sample sizes, however, most of the studies were
high quality, reporting favorable results for melatonin
use. Subsequently, the SMEs provide a weak recommen-
dation in favor of melatonin use in a healthy population
for promoting sleep.
Daytime sleepiness/somnolence
All five studies investigating daytime sleepiness or som-
nolence were high quality, and four [51,56-58] of the five
small studies favored melatonin over the control. The
one study not favoring melatonin [50] was poorly pow-
ered, with a sample size of (n = 10 subjects). Because no
information was reported on the frequency or severity of
adverse events in any of these studies, safety is not well
understood. Although this group of studies suffered
from small sample sizes, methodological quality was
high. As a result, the SMEs provided a weak recommen-
dation in favor of melatonin use to improve daytime
sleepiness in healthy people.
Phase shift/hormone changes
The five studies investigating the effects of a nighttime
dose of melatonin on phase shift/ hormone changes in
healthy populations were more physiologically-based
with primary outcomes being a change in the bio-
markers being studied, and had severe limitations in
study quality compared to the other two groups. Two
[60,61] of the five studies were low quality due to meth-
odological flaws in reporting of randomization, conceal-
ment, and dropout rates. The remaining three [59,62,63]
studies were high quality; however, the sample sizes for
all five studies were fairly low. Because neither adverse
events nor effect sizes were reported in any of the stud-
ies, this information remains unknown. Given this lack
of information, the SMEs could not provide any recom-
mendation for the use of melatonin to improve hormo-
nal phase shift changes in healthy people.Additional dietary supplement design elements
The authors looked at additional design elements thought
to be important for understanding the specific effects re-
lated to dietary supplements (Table 4). None of the studies
in shift workers or jet lagged populations reported infor-
mation on baseline diet exposures, but two [46,47] studies
on insomnia and two [52,62]in healthy populations re-
ported this information. Four [38-40,43] jet lag studies
controlled for background diets during the study, com-
pared to nine [49,51,53,57-59,61-63] studies in healthy
volunteers, none in insomnia, and three [29,33,35] studies
in shift workers. Several studies reported that they did not
control for background diets: one jet lag [42]; one insom-
nia [46]; one shift worker [34], and two [52,55] healthy
volunteer studies; the remaining did not report on this in-
formation. In four [29,40,53,57] studies, subjects abstained
from caffeine and three [43,58,62] studies allowed, but
limited caffeine use. Formulation of the melatonin for the
intervention was described in 57% of the papers, including
five [29,30,33,34,36] shift worker, one [40] jet lag, three
[45-47] insomnia, and 11 [49,50,52,53,55-57,59,60,62,63]
healthy volunteer studies. Melatonin supplement purity
was analyzed in one [33] shift worker, two [38,40] jet lag,
no insomnia, and three [50,53,60] healthy volunteer stud-
ies. Finally, analysis of proper absorption of melatonin was
conducted in one [35] shift worker, one [37] jet lag, two
[45,46] insomnia, and nine [45,49,52,53,55,58-60,63]
healthy volunteer studies.
Outcome measures
A total of 31 unique assessment tools, including 19 sub-
jective and 12 objective measures, were utilized to
measure sleep outcomes (see Table 5). Although three
of the 12 objective measures were of great interest, they
were not relevant outcomes of interest in this review -
melatonin measurements in saliva, blood, and urine.
Thirteen studies [32,35,36,40,42,45,48,49,53,54,58,59,62]
used a combination of both subjective and objective as-
sessment tools to evaluate outcomes and 85.0% of these
studies received high quality scores. Twenty studies
[29-31,33,34,37-39,41,42,44,46,47,50-52,55-57,61], 80%
of which included high quality scores, used only subject-
ive assessment tools; four [50,51,60,63] studies, three of
which were high quality, used only objective assessment
tools.
Dosing as reported in the literature
The amount of melatonin provided, and frequency of
administration reported in the included studies varied
greatly. Oral preparations were used in amounts ranging
from 0.3 to 10.0 mg/day. All except two [53,61] studies
used capsules, with 72% failing to indicate the type of
capsule (e.g. hard or soft) used. Two [33,43] studies uti-
lized fast-release preparations in amounts ranging from
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sustained-release formulation in amounts ranging from
0.3 to 6.0 mg, and one [53] study utilized a patch prepar-
ation providing 2.1 mg. Only one [61] study utilized a
drink preparation, where 2 mg of melatonin was pro-
vided in 100 ml of 1% ethanol in water.
Discussion
Previous research suggests that supplementation with
melatonin may help increase total sleep time in individ-
uals suffering from sleep restriction or altered sleep
schedules; relieve daytime fatigue associated with jet lag;
reset the body’s sleep-wake cycle; and reduce the time it
takes to fall asleep in people with delayed sleep phase
syndrome [64]. In fact, a number of meta-analyses have
been published to evaluate the efficacy and safety of ex-
ogenous melatonin for subjects with primary sleep disor-
ders [65,66], and include a range of population groups
for the outcomes of sleep onset latency, total sleep dur-
ation and sleep efficiency [65] and for the prevention
and treatment of jet lag [65]. The inclusion and exclu-
sion criteria vary for each of these meta-analyses. In con-
trast to earlier meta-analyses, the authors of this review
investigated the use of melatonin in military and civilian
populations across various sleep behaviors, and divided
the included literature into four distinct user groups:
shift workers, individuals experiencing jet lag, persons
suffering from insomnia, and healthy individuals who
want to improve their sleep; although the review focused
on healthy populations, the authors chose to include in-
somnia populations as many military personnel who
have been deployed may experience some form of in-
somnia [67].
Unfortunately, only two studies in this review were
conducted in military populations: one study evaluated
melatonin for jet lag in a US Air Force Reserve Unit [40]
and the other assessed melatonin for sleep efficacy in
the Canadian military [25]. Importantly, both were of
high quality and utilized both subjective and objective
measures. The authors encourage more research in this
population, but suggest that the way the authors divided
the literature into user groups can be useful for making
generalizations for the military exposed to disruptions in
sleep behavior.
Besides the limited amount of studies available in the
literature that were directly on military populations ex-
posed to melatonin and were needed to make general-
izations for this specific population, another limitation
of this review is that, unlike traditional systematic re-
views, the REAL process only includes RCT and system-
atic review study designs accessible in current English
electronic databases. Although the inclusion of only
English literature and exclusion of gray literature may be
seen as a limitation, research has shown that doing sodoes not seriously compromise the implications for the
majority of interventions and claims [68-71]; thus
REALs and systematic reviews are usually comparable
and result in the same “bottom line” conclusions about
the evidence [72].
Overall, results from this review suggest that mela-
tonin shows promise to prevent phase shifts from jet lag
and improve insomnia in otherwise healthy adults, but
to a limited extent; the use of melatonin in shift workers
is inconclusive. According to the authors’ GRADE ana-
lysis, no recommendations could be provided in favor of
melatonin with regard to promoting beneficial sleep out-
comes in shift workers. More high quality studies with
large sample sizes and power are needed to increase the
confidence in the estimate of the effect. Although no
recommendation that melatonin can improve sleep out-
comes in shift workers can be made at this time, the use
of melatonin in healthy adults shows potential in pre-
venting phase shifts due to jet lag. Due to these limita-
tions and the quality of the literature, our confidence in
the estimate of the effect is moderate. A weak recom-
mendation in favor of melatonin for use on sleep out-
comes in jet lagged populations is noted.
Although the purpose of the review was to look at
healthy adults, the authors also explored whether mela-
tonin could be a viable treatment option for insomnia
because the consequences of insomnia are detrimental
and associated with other comorbidities. All four insom-
nia studies showed positive effects, despite small sample
sizes; thus a weak recommendation with moderate confi-
dence in favor of melatonin is made for individuals with
insomnia for improving sleep outcomes. More studies
with high quality, large sample sizes are needed to in-
crease the confidence in the estimate of the effect.
For the studies with exclusively healthy volunteers, a
weak recommendation was made in favor of melatonin
use for initiating sleep or sleep efficacy, again, despite
sample sizes and low power. A weak recommendation
with moderate confidence was made in favor of mela-
tonin use in healthy populations for daytime sleepiness
or somnolence. In contrast, studies on phase shift/hor-
mone changes in healthy populations were primarily of
low quality with small sample sizes. As such, no conclu-
sions can be drawn regarding melatonin’s effects on pro-
ducing phase shifts or hormone changes in healthy
populations at this time. Clearly more research will be
needed to strengthen this information.
Whereas the majority (83.0%) of the studies included in
this review were deemed as relatively good quality and
limited to healthy adults, great heterogeneity existed in
terms of sample sizes, assessment tools, and administra-
tion of melatonin (i.e., dose, frequency, type of prepar-
ation, timing). Although most of the assessment tools
aligned with good quality studies, their lack of robustness
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fect sizes for the outcomes. Finally, although the studies
were reviewed by specific indications of use (i.e., in shift
work, jet lag, insomnia, or healthy volunteers) the residual
variability coupled with the above issues may have limited
the conclusions that could be drawn. For example, the ef-
fects of melatonin may benefit military personnel given
their training and deployment requirements, and prove to
be a safe intervention to promote sleep – in both warfigh-
ters and family members with sleep issues; however, the
lack of studies including military populations prevents the
authors from making definitive conclusions regarding the
usage of melatonin in these populations. A natural sleep
aid with limited side effects would be far more advanta-
geous than a prescription sleep drug with clearly described
frequent and/or rare, unexpected side effects.
Three physiologic effects: 1) promotion of sleep onset; 2)
maintenance of sleep; and 3) phase-shifting of circadia
rhythms - an indirect action - and the diurnal rhythm in
melatonin itself [70] have been associated with melatonin
administration. Melatonin has a distinct daily secretion
rhythm that is determined by the sleep-wake and light–
dark cycles. Nighttime exposure to bright lights phase shifts
the human circadian rhythms (core temperature, cortisol
and melatonin) with a maximal effect occurring in early
morning when the nadir in the body’s core temperature is
achieved. Administration of melatonin has an opposite ef-
fect in that melatonin can reduce or completely block the
phase shift alterations in circadian rhythms induced by
bright light. [73] Physiologic administration of melatonin
(i.e., 0.1 to 0.3 mg) has been shown to affect both sleep on-
set and maintenance qualities, whereas larger amounts (i.e.,
0.5 mg) affect the phase-shifting actions of melatonin. Very
small oral amounts (i.e., 0.3 mg or less) of melatonin can
raise daytime plasma melatonin to night-time levels [74],
which is important as acute and transient hypothermia in-
duced by exogenously administered melatonin may be crit-
ical in the circadian phase shifting and hypnogenic actions
of melatonin. Because the clinical administration of mela-
tonin (i.e., 0.5, 3.0 and 9.0 mg doses in the daytime) has
been shown to induce hypothermia in a dose-dependent
manner [75], its use as a potential natural sleep therapy
within the military may be limited when personnel are in
cold environments, when hypothermia induced by the cold
and a state of sleepiness/drowsiness could greatly affect
multiple areas of performance.
As noted above, many different melatonin preparations
were used throughout the included studies to include fast
[33,42] and long [35,62] acting formulations, a melatonin
patch [53] and a drink intervention [61]. These diverse
preparations may have contributed to the effect size of the
outcome measures. The pharmacokinetic properties of
melatonin preparations can vary depending on the lipid
solubility of the accompanying inert ingredients, and affecttheir bioavailability: 1 to 10 mg can raise plasma mela-
tonin levels 3 to 60 times their normal peaks [74]. Import-
antly, exogenous melatonin undergoes extensive and rapid
first-pass metabolism (approximately 30-60%) in the liver
where it is first oxidized to 6-hydroxy melatonin by P450-
dependent microsomal oxidases, and then largely con-
verted to a sulfate or glucuronide derivative before being
excreted into the urine or feces; about 2-3% is excreted
unchanged into the urine or saliva [74]. Melatonin can be
absorbed transdermally, but time to peak blood levels is
delayed. Concentrations of melatonin vary across the 24-
hour period with plasma levels peaking at night (~50-
200 pg/ml) or a 10- to 50-fold increase from the daytime
levels [76]. However, significant individual differences in
peak melatonin levels after a standardized administration
have been noted. In the most recent meta-analysis [66],
the meta-regression technique was used to discern that
higher melatonin amounts and longer duration trials were
related to significantly greater effect sizes on sleep latency
and total sleep time in subjects with primary sleep disor-
ders than lower amounts. Urinary metabolites and saliva
measures have also been utilized in clinical studies. The
wide variety of methods reported in the literature for
measuring melatonin in humans has increased the diffi-
culty of comparing results across different studies; guide-
lines for the measurement and reporting of studies
utilizing melatonin preparations have been recommended
in order to advance the field [77].
Although no serious adverse events or health risks from
melatonin use were noted in this review, potential detri-
mental health effects associated with using melatonin
should be addressed. In healthy subjects, daytime adminis-
tration of oral melatonin (0.1 to 1.0 mg) produced signifi-
cant drowsiness, fatigue, and performance decrements,
which appear to peak approximately three to four hours
after ingestion [64,78].
Melatonin has also been shown to reduce body
temperature [10,64,79], which could preclude its use under
conditions of cold stress. Also, use of melatonin could
result in central nervous system (e.g., somnolence, head-
aches, increased frequency of seizures, nightmares), cardio-
vascular (e.g., hypotension or hypertension), gastrointestinal
(e.g., diarrhea, abdominal pain), and dermatological effects
[78,79]. If melatonin is used for daytime sleep promotion,
unwanted circadian phase shifts could occur; and if used to
accelerate circadian phase shifts, potential unwelcome sleep
promotion might occur [79]. Use of melatonin to promote
daytime sleep may not be appropriate in certain military sit-
uations, and benefits and risks of use would need to be
evaluated in the context of the mission.
Conclusions
This review was conducted to critically assess the avail-
able peer-reviewed literature on the use of melatonin in
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termine whether melatonin might be useful in military
populations. The review was limited by the inclusion of
only two, though high quality, studies derived from mili-
tary populations, which makes generalizations to the
military less robust. Additionally, the REAL process only
included RCTs published in the English language which
may have limited the depth of the review. Although the
majority of the studies in this review were relatively high
quality and limited to healthy adults, great heterogeneity
existed in terms of sample sizes, assessment tools, and
the range of melatonin dosages administered.
The use of melatonin by healthy adults shows promise
to prevent phase shifts from jet lag and improvements in
insomnia, but to a limited extent. For the initiation of
sleep and sleep efficacy, the data cannot yet confirm a
positive benefit. No recommendation can be proposed
for the use of melatonin in shift workers. Melatonin in a
wide array of preparations and amounts demonstrates
few significant and limiting adverse events. Because
melatonin has a very low side effect profile and limited
evidence of habituation and tolerance, its use in Service
Members could be considered for specific tasks. How-
ever, additional randomized controlled trials with larger
sample sizes, common assessment tools, and well-
characterized interventions in physiologic dose ranges in
military populations would be needed for confirmation.
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